))
Navigating FDA's clinical trial expectations after approval
Manage episode 434037207 series 3506216
コンテンツは Darshan Kulkarni によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Darshan Kulkarni またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Today, we're diving into the FDA's Fiscal Year 2022 report on postmarketing requirements (PMRs) and postmarketing commitments (PMCs).
PMRs are mandatory studies required by the FDA after a drug's approval, focusing on real-world data for long-term safety and effectiveness. Think of them as an extension of the initial research phase, but in a real-world setting. PMCs, while not legally mandated, are additional studies agreed upon by the drug developer, providing valuable insights.
Both PMRs and PMCs are essential for ensuring the safety and efficacy of medications.
For clinical research sites, adhering to these protocols can be challenging but offers opportunities to showcase expertise and attract more research partnerships.
For Sponsors: Sponsors must manage the costs and potential delays, but the insights gained can strengthen product value and regulatory trust.
For CROs: CROs need to stay compliant and adapt to these requirements to secure lucrative collaborations.
Join us as we explore the latest FDA report and its implications for everyone in the clinical research arena. Don't miss out on understanding how these regulations shape the future of medical treatments and industry collaborations!
104 つのエピソード
シェア
